CKDX.F Stock Overview
A clinical-stage biopharmaceutical company, develops and commercializes drugs for eye diseases in Australia and the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
Opthea Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.44 |
| 52 Week High | AU$0.57 |
| 52 Week Low | AU$0.44 |
| Beta | 1.54 |
| 11 Month Change | -22.81% |
| 3 Month Change | n/a |
| 1 Year Change | 51.72% |
| 33 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -20.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| CKDX.F | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0% | -6.5% | -1.0% |
| 1Y | 51.7% | 14.6% | 30.3% |
Return vs Industry: CKDX.F exceeded the US Biotechs industry which returned 14.6% over the past year.
Return vs Market: CKDX.F exceeded the US Market which returned 30.3% over the past year.
Price Volatility
| CKDX.F volatility | |
|---|---|
| CKDX.F Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.7% |
| Market Average Movement | 6.2% |
| 10% most volatile stocks in US Market | 15.7% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: CKDX.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine CKDX.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1984 | 33 | Fred Guerard | opthea.com |
Opthea Limited, a clinical-stage biopharmaceutical company, develops and commercializes drugs for eye diseases in Australia and the United States. Its development activities are based on the intellectual property portfolio covering vascular endothelial growth factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. The company’s lead product candidate is sozinibercept (OPT-302), a biologic drug in Phase 3 clinical trials designed to inhibit VEGF-C and VEGF-D and complement VEGF-A inhibitors for the treatment of wet age-related macular degeneration and diabetic macular edema.
Opthea Limited Fundamentals Summary
| CKDX.F fundamental statistics | |
|---|---|
| Market cap | US$529.09m |
| Earnings (TTM) | -US$220.24m |
| Revenue (TTM) | US$261.86k |
1,913x
P/S Ratio-2.3x
P/E RatioIs CKDX.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CKDX.F income statement (TTM) | |
|---|---|
| Revenue | US$261.86k |
| Cost of Revenue | US$0 |
| Gross Profit | US$261.86k |
| Other Expenses | US$220.50m |
| Earnings | -US$220.24m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.18 |
| Gross Margin | 100.00% |
| Net Profit Margin | -84,107.14% |
| Debt/Equity Ratio | -264.5% |
How did CKDX.F perform over the long term?
See historical performance and comparison